IL2 and metastatic melanoma: An ongoing phase II study has the aim of exploring the efficacy of HD IL-2 in combination with low dose ipilimumab followed sequentially by nivolumab in patients with unresectable or metastatic melanoma who had progressed on prior anti-PD1 therapy (NCT04562129).